

## Biomimetic Cyclization of Cnicin to Malacitanolide, a Cytotoxic Eudesmanolide from *Centaurea malacitana*

Alejandro F. Barrero,\* J. Enrique Oltra, Víctor Morales, and Miriam Álvarez

Departamento de Química Orgánica, Facultad de Ciencias, Universidad de Granada, 18071 Granada, Spain

Ignacio Rodríguez-García

Departamento de Química Orgánica, Facultad de Ciencias Experimentales, Universidad de Almería, 04120 Almería, Spain

Received January 13, 1997<sup>®</sup>


Malacitanolide (**2**), a new eudesmanolide isolated from the aerial parts of *Centaurea malacitana*, was characterized spectroscopically. The synthesis of **2** from cnicin (**1**), via the epoxide **3**, confirmed the structure and stereochemistry of malacitanolide, as well as its biogenetic relationship with **1**. Cytotoxic activity values for **2** are significantly higher than for **1**.

*Centaurea malacitana* Boiss. (Compositae) contains cnicin (**1**) and other cytotoxic and antimicrobial germacranolides<sup>1</sup> that are useful for the semisynthesis of (+)-vernolepin related compounds.<sup>2</sup> Further investigation of the extract of *C. malacitana* led to the isolation of malacitanolide (**2**), a new eudesmanolide with potent cytotoxic activity, and 8-*O*-(4-acetoxiangeloyl)salonitenolide,<sup>3</sup> here described for the second time in nature.

The molecular formula of malacitanolide (**2**) is C<sub>20</sub>H<sub>26</sub>O<sub>8</sub> as deduced from its HRCIMS. Its IR spectrum showed bands due to hydroxyl, aldehyde,  $\delta$ -lactone, and  $\alpha,\beta$ -unsaturated ester groups. In the CIMS, peaks at  $m/z$  281 [M + H - C<sub>5</sub>H<sub>6</sub>O<sub>3</sub>]<sup>+</sup>, 263 [M + H - C<sub>5</sub>H<sub>8</sub>O<sub>4</sub>]<sup>+</sup>, and 115 [C<sub>5</sub>H<sub>7</sub>O<sub>3</sub>]<sup>+</sup> were indicative of a five-carbon-atom dihydroxylated-ester side chain. The <sup>1</sup>H-NMR spectrum showed signals confirming the presence, at C-8, of the same side chain that occurs in **1**.<sup>1</sup> However, the chemical shift of H-14 (0.93 ppm) was the usual one for eudesmanolides.<sup>4</sup> The <sup>13</sup>C-NMR spectrum confirmed the eudesmanolide skeleton.<sup>5</sup> Additionally, the <sup>1</sup>H-NMR spectrum showed signals ( $\delta$  3.42 and 2.82), which could be justified if an equatorial hydroxyl group was located at C-1 and an axial formyl group was present at C-4. Chemical shift and multiplicity of H-15 confirmed the  $\beta$  axial orientation of the aldehyde.<sup>4</sup> The coupling constants between H-5, H-6, H-7, and H-8 were the ones expected if they all had axial orientations. These data suggested structure **2** for malacitanolide. Several NOE experiments confirmed the relative configuration of **2** and the position and preferential conformation of the formyl group (Scheme 1).

A biogenetic precursor of malacitanolide (**2**) could be cnicin (**1**), which, after enzymatic epoxidation, stereospecific transannular cyclization of the 1,10-epoxide, and hydride shift, would yield **2**. In order to support this hypothesis and to confirm the structure of malacitanolide, chemical synthesis of **2** from **1** was performed (Scheme 1). Treatment of **1** with *m*-CPBA, in the presence of pyridine, led to the oxirane **3**. In the <sup>1</sup>H-NMR spectrum of **3**, H-1 appeared at  $\delta$  2.89 (dd) and the Me-14 at  $\delta$  1.25 (s), the expected values considering the presence of epoxide carbons at C-1 and C-10.<sup>6</sup> The 1 $\beta$ ,10 $\alpha$  stereochemistry of the epoxide was proposed

**Scheme 1.** Biomimetic cyclization of **1** to **2**, via the epoxide **3**.



considering the preferential conformation of germacranolides,<sup>7</sup> the reaction mechanism of *m*-CPBA, and the coupling constants of H-1. When **1** was treated with *m*-CPBA without pyridine, malacitanolide was directly obtained. Apparently, *m*-chlorobenzoic acid, formed during the epoxidation reaction, was responsible for the electrophilic opening and subsequent rearrangement of epoxide **3** (Scheme 1). As the absolute configuration of (+)-cnicin (**1**) has been reported,<sup>8</sup> the synthesis of (+)-malacitanolide (**2**) from **1** confirms the absolute configuration of **2** and supports its biogenetic relationship with cnicin.

In vitro cytotoxic activity of **2** was assayed<sup>9</sup> towards the P-388, SCHABEL, A-549, HT-29, and MEL-28 tumor cell lines. Malacitanolide (**2**) showed IC<sub>50</sub> = 3.05 × 10<sup>-7</sup> M in the five cases. Previously reported IC<sub>50</sub> values for cnicin (**1**) were 6.6 × 10<sup>-6</sup> M against the P-388 cells and 1.32 × 10<sup>-5</sup> M towards both the A-549 and HT-29 lines.<sup>1</sup> It is generally accepted that the cytotoxic activity of the sesquiterpene lactones resides chiefly on their Michael acceptor groups.<sup>10</sup> However, although **2** and **1** have identical Michael acceptor groups, **2** has an activity twenty to forty times higher than **1** towards the P-388, A-549, and HT-29 lines. This increase in activity could be due either to the new functionalization pattern or to the higher molecular rigidity.

### Experimental Section

**General Experimental Procedures.** Optical rotations were determined on a Perkin-Elmer 141 polarim-

\* Phone: 34-58-243318. Fax: 34-58-243320. E-mail: afbarre@goliat.ugr.es.

<sup>®</sup> Abstract published in *Advance ACS Abstracts*, August 15, 1997.

eter. IR spectra were obtained, in liquid film between NaCl plates, on a 983 G Perkin-Elmer apparatus. HRMS were measured on a Autospec-Q VG-Analytical (FISONS) mass spectrometer, and LRMS were determined on a 5988A Hewlett-Packard instrument. NMR spectra were recorded on a Bruker AM 300 spectrometer. Chemical shifts are reported in parts per million ( $\delta$ ) relative to TMS, and coupling constants ( $J$ ) are in Hertz. Carbon substitution degrees were established by DEPT multipulse sequence. TLC was performed on precoated 0.25-mm thick Merck plates of Si gel 60 F<sub>254</sub>, using a 7% phosphomolybdic acid solution (EtOH) to visualize the spots. Gravity column chromatography was carried out on Merck Si gel 60 (70–230 mesh), and flash chromatography was performed as described previously.<sup>11</sup>

### Plant Material

*C. malacitana* was collected in Carataunas, Granada, Spain, in June 1996, and was taxonomically identified by Prof. G. Blanca (Departamento de Biología Vegetal, Universidad de Granada, Spain). A voucher specimen (no. 40128) is deposited at the Herbarium of the Faculty of Sciences of the University of Granada.

### Extraction and Isolation

The aerial parts of the plants were air-dried, ground, and extracted with *t*-BuOMe in a Soxhlet apparatus (5.4 kg furnished 157.5 g of extract). A portion (10 g) of the extract was subjected to column chromatography over 110 g Si gel using a CHCl<sub>3</sub>–Me<sub>2</sub>CO gradient. The following sesquiterpene lactones were isolated: 8-*O*-(4-acetoxangeloyl)salonitenolide<sup>3</sup> (10 mg, CHCl<sub>3</sub>–Me<sub>2</sub>CO 9:1), cnicin 4'-*O*-acetate<sup>12</sup> (1.85 g, CHCl<sub>3</sub>–Me<sub>2</sub>CO 9:1), stenophyllolide<sup>13</sup> (1.45 g, CHCl<sub>3</sub>–Me<sub>2</sub>CO 5:5), cnicin (**1**)<sup>1</sup> (2.06 g, CHCl<sub>3</sub>–Me<sub>2</sub>CO 4:6), and malacitanolide (**2**) (90 mg, CHCl<sub>3</sub>–Me<sub>2</sub>CO 35:65).

**Malacitanolide (2):** [ $\alpha$ ]<sub>D</sub><sup>25</sup> +96° (*c* 1.02, MeOH); IR (dry film)  $\nu_{\max}$  3412, 2733, 1766, 1718 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz)  $\delta$  9.96 (1H, s, H-15), 6.39 (1H, s, H-5'a), 6.20 (1H, d,  $J$  = 3.1 Hz, H-13a), 6.08 (1H, s, H-5'b), 5.59 (1H, d,  $J$  = 2.9 Hz, H-13b), 5.31 (1H, td,  $J$  = 11.0, 4.4 Hz, H-8), 4.65 (1H, m, H-3'), 4.55 (1H, dd,  $J$  = 11.8, 11.0 Hz, H-6), 3.85 (1H, dd,  $J$  = 11.1, 3.3 Hz, H-4'a), 3.61 (1H, dd,  $J$  = 11.1, 6.7 Hz, H-4'b), 3.42 (1H, dd,  $J$  = 10.9, 4.2 Hz, H-1), 2.90 (1H, tt,  $J$  = 11.0, 3.0 Hz, H-7), 2.82 (1H, td,  $J$  = 5.6, 1.5 Hz, H-4), 2.50 (1H, dd,  $J$  = 12.8, 4.4 Hz, H-9), 2.05 (1H, dd,  $J$  = 11.8, 5.6 Hz, H-5), 0.93 (3H, s, H-14); NOE-difference, proton irradiated (NOEs observed) H-1 (H-5), H-4 (H-5, H-15), H-5 (H-1, H-4, H-7), H-6 (H-8, H-14, H-15), H-7 (H-5), H-8 (H-6, H-14), H-15 (H-4, H-6, H-14); <sup>13</sup>C NMR [(CD<sub>3</sub>)<sub>2</sub>SO, 75 MHz]  $\delta$  203.7 (d, C-15), 169.3 (s, C-12), 165.2 (s, C-1'), 141.9 (s, C-2'), 137.5 (s, C-11), 125.3 (t, C-5'), 118.7 (t, C-13), 76.0 (d, C-6), 75.9 (d, C-1), 70.2 (d, C-3'), 69.5 (d, C-8), 65.4 (t, C-4'), 52.3 (d, C-7), 47.2 (d, C-5), 44.7 (d, C-4), 43.4 (t, C-9), 41.0 (s, C-10), 26.7 (t, C-2), 21.8 (t, C-3), 13.4 (q, C-14); the <sup>13</sup>C-NMR data were assigned through analysis of 2D NMR spectra (HETCOR and HMBC) of **2**; CIMS  $m/z$  395 [M + H]<sup>+</sup> (1), 281 (23), 263 (42), 245 (44), 115 (100), 97 (98), 55 (53); HRCIMS  $m/z$  395.1705 (calcd for C<sub>20</sub>H<sub>27</sub>O<sub>8</sub> 395.1706).

**Epoxidation Reactions of Cnicin (1).** *m*-CPBA (160 mg) was added to a solution of **1** (200 mg) in 5 mL of THF and 0.1 mL of pyridine. The mixture was stirred

for 30 min at room temperature, and the solvent was removed *in vacuo*; then H<sub>2</sub>O (10 mL) was added to the residue, and the mixture was extracted with EtOAc. Evaporation of the organic solvent gave 103 mg of epoxide **3**: <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>CO, 300 MHz]  $\delta$  6.32 (1H, s, H-5'a), 6.10 (1H, s, H-5'b), 6.09 (1H, d,  $J$  = 3.1 Hz, H-13a), 5.75 (1H, d,  $J$  = 3.3 Hz, H-13b), 5.49 (1H, d,  $J$  = 9.8 Hz, H-5), 5.41 (1H, dd,  $J$  = 9.8, 8.5 Hz, H-6), 5.17 (1H, br t,  $J$  = 8.5 Hz, H-8), 4.55 (1H, m, H-3'), 4.42 (1H, d,  $J$  = 14.0 Hz, H-15a), 4.26 (1H, d,  $J$  = 14.0 Hz, H-15b), 3.76 (1H, dd,  $J$  = 11.1, 3.3 Hz, H-4'a), 3.48 (1H, dd,  $J$  = 11.1, 6.7 Hz, H-4'b), 3.31 (1H, tt,  $J$  = 8.5, 3.2 Hz, H-7), 2.89 (1H, dd,  $J$  = 11.3, 2.4 Hz, H-1), 1.25 (3H, s, H-14); <sup>13</sup>C NMR [(CD<sub>3</sub>)<sub>2</sub>CO, 75 MHz]  $\delta$  170.1 (s, C-12), 165.6 (s, C-1'), 147.6 (s, C-4), 141.8 (s, C-2'), 137.3 (s, C-11), 126.8 (t, C-5'), 125.5 (d, C-5), 123.8 (t, C-13), 76.7 (d, C-6), 72.3 (d, C-8), 71.5 (d, C-3'), 67.4 (d, C-1), 66.6 (t, C-4), 60.9 (t, C-15), 58.9 (s, C-10), 54.1 (d, C-7), 48.1 (t, C-9), 32.2 (t, C-3), 25.6 (t, C-2), 17.5 (q, C-14); HR-FABMS  $m/z$  395.1696 (calcd for C<sub>20</sub>H<sub>27</sub>O<sub>8</sub>, 395.1706).

*m*-CPBA (160 mg) was added to **1** (200 mg) in 5 mL of THF and the mixture was stirred for 30 min at room temperature. Evaporation of the solvent generated 360 mg of a residue containing *m*-chlorobenzoic acid and **2** (<sup>1</sup>H NMR). The residue was flash chromatographed (CHCl<sub>3</sub>–Me<sub>2</sub>CO 6:4), giving 58 mg of pure **2**, identical in all respects to natural **2**, including optical rotation.

**Cytotoxicity Assays.** The *in vitro* cytotoxic activities of 8-*O*-(4-acetoxangeloyl)salonitenolide and **2** were assayed<sup>9</sup> towards P-388 and SCHABEL mouse lymphomas and towards the A-549 (lung carcinoma), HT-29 (colon carcinoma), and MEL-28 (melanoma) human cell lines. 8-*O*-(4-Acetoxangeloyl)salonitenolide showed IC<sub>50</sub> = 2.5  $\mu$ g/mL against both mouse lymphomas and IC<sub>50</sub> = 5  $\mu$ g/mL towards the three human cell lines. Compound **2** showed IC<sub>50</sub> = 0.12  $\mu$ g/mL in all cases.

**Acknowledgment.** Our thanks go to Dr. D. G. Grávalos for the cytotoxicity analyses, to the Spanish DGICYT for the Research Program PB 95/1192, and to the Spanish Ministerio de Educacion y Cultura for the grant provided to M. Alvarez.

### References and Notes

- Barrero, A. F.; Oltra, J. E.; Rodríguez, I.; Barragán, A.; Grávalos, D. G.; Ruiz, P. *Fitoterapia* **1995**, *66*, 227–230.
- Barrero, A. F.; Oltra, J. E.; Barragán, A. *Tetrahedron Lett.* **1995**, *36*, 311–314.
- Marco, J. A.; Sanz, J. F.; Sancenón, F.; Yuste, A.; Cardá, M. *Phytochem. (Life Sci. Adv.)* **1992**, *11*, 159–169.
- Rustayan, A.; Ahmadi, B.; Jakupovic, J.; Bohlman, F. *Phytochemistry* **1986**, *25*, 1659–1662.
- Shimizu, S.; Miyase, T.; Ueno, A.; Usmanghani, K.; *Phytochemistry* **1989**, *28*, 3399–3402.
- Rodríguez, A. A. S.; García, M.; Rabi, J. A.; *Phytochemistry* **1978**, *17*, 953–954.
- Watson, W. H.; Kashyap, R. P. *J. Org. Chem.* **1986**, *56*, 2521–2524.
- Adekenov, S. M.; Gatilov, Yu. V.; Bagryanskaya, I. Yu.; Raldugin, V. A. *Sib. Khim. Zh.* **1993**, *76*–79. *Chem. Abstr.* **1993**, *119*, 181139p.
- Berengeron, R. I.; Davanaugh, Jr., P. F.; Kline, S. J.; Hughes, Jr., R. G.; Elliot, G. T.; Porter, C. W. *Biochem. Biophys. Res. Commun.* **1984**, *121*, 848–854.
- Hoffmann, H. M. R.; Rabe, J. *Angew. Chem. Int. Ed. Engl.* **1985**, *24*, 94–110.
- Still, W. C.; Kahn, M.; Mitra, A. *J. Org. Chem.* **1978**, *43*, 2923–2925.
- Bruno, M.; Herz, W. *Phytochemistry* **1988**, *27*, 1873–1875.
- Picher, M. T.; Seoane, E.; Tortajada, A. *Phytochemistry* **1984**, *23*, 1995–1998.